Company: AEMD
Filing Date: 2025-06-26
Form Type: 10-K
Source: 0001683168-25-004780
Chunk: 506

Company: AETHLON MEDICAL INC
Filing Date: 2025-06-26
Form: 10-K
Item: Item 1C
Chunk 506
---
 (decrease) in cash and cash equivalents and restricted cash 
     69,590  
     (9,090,965)

    Cash and cash equivalents restricted cash at beginning of year 
     5,529,484  
     14,620,449 

    Cash and cash equivalents and restricted cash at end of year 
    $5,599,074  
    $5,529,484 

    Supplemental information of non-cash investing and financing activities: 

    Issuance of shares under vested restricted stock units, net stock option exercises and unvested share issuance for services 
    $13  
    $35 
  
    Disposal of fully depreciated property 
    $350,670  
    $– 
  
    Reversal of accrued commission liability (see Note 6) 
    $–  
    $404,120 
  
    Deferred offering costs not yet paid 
    $–  
    $219,117 

    Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets: 

    Cash and cash equivalents 
    $5,501,261  
    $5,441,978 
  
    Restricted cash 
     97,813  
     87,506 
  
    Cash and restricted cash 
    $5,599,074  
    $5,529,484 

See accompanying notes to the consolidated financial
statements.

 F-8 

Aethlon Medical, Inc. and Subsidiary

Notes to Consolidated Financial Statements

1. ORGANIZATION, LIQUIDITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

ORGANIZATION

Aethlon Medical, Inc. (“Aethlon,”
the “Company,” “we” or “us”) is a medical therapeutic company focused on developing the Hemopurifier,
a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections and with additional potential
applications e in organ transplantation and other areas of significant unmet needs. In human studies, 164 sessions with 38 patients, the
Hemopurifier was safely utilized and demonstrated the potential to remove life-threatening viruses. In pre-clinical studies, the Hemopurifier
has demonstrated the potential to remove harmful exosomes and exosomal particles from biological fluids, utilizing its proprietary lectin-based
technology. This action has potential applications in cancer, where exosomes and ex